Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes

Impact of Inflammation on Brain Volume in Multiple Sclerosis

(2012) Jojy Cheriyan   ARCHIVES OF NEUROLOGY

Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis

(2011) M Calabrese et al.   Multiple Sclerosis Journal

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis

(2011) Carolina Holmén et al.   Multiple Sclerosis Journal

Natalizumab Reduces Clinical and MRI Activity in Multiple Sclerosis Patients with High Disease Activity: Results from a Multicenter Study in Switzerland

(2010) Norman Putzki et al.   EUROPEAN NEUROLOGY

Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study

(2010) F. Sangalli et al.   NEUROLOGICAL SCIENCES

Three years of experience: the Italian registry and safety data update

(2010) G. L. Mancardi et al.   NEUROLOGICAL SCIENCES

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study

(2009) A. B. Oturai et al.   EUROPEAN JOURNAL OF NEUROLOGY

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries

(2009) N. Putzki et al.   EUROPEAN JOURNAL OF NEUROLOGY

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

(2008) R. Zivadinov et al.   NEUROLOGY